Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1
'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.'
Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin.
Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters.
Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities.
About amycretin
Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss.
About the phase 1b/2a subcutaneous amycretin trial
The phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1
About the phase 1 oral amycretin trial
The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2
About obesity
Obesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7
The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.
Contacts for further information
References
© 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025
View original content to download multimedia: https://www.prnewswire.com/news-releases/novo-nordisk-advances-early-stage-obesity-medication-amycretin-to-phase-3-clinical-development-based-on-early-phase-clinical-trial-results-in-people-with-obesity-or-excess-weight-published-in-the-lancet-302487500.html
SOURCE NOVO NORDISK INC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Symptoms of climate change such as extreme heat can impact insect activity
Climate change symptoms like rising temperatures in Augusta are affecting gnat and other insect activity. 'Changing Climate can affect them in some ways,' said Elmer Gray, entomologist, at the University of Georgia. 'One thing that's going to help them is staying warm at night. Wednesday night I don't know if it got below 77 degrees. We know that insects like warmer temperatures. Warmer temperatures mean a longer growing season.' Gray added, 'They may grow longer into the fall, if it stays warmer into October. So they'll have more chances to create more generations in a life cycle.' Gray said insects need humidity. 'We've had so much rain throughout the end of spring and into the beginning of summer,' said Gray. 'The temperatures have warmed up, so everything is starting to grow faster. They completed their life cycle quicker. When we have lots of moisture in the environment, whether it's in the soil, standing water collecting in containers, all of these things provide habitats that increase the productivity of a wide range of insects.' 'The term gnat is kind of interesting,' said Gray. 'Gnat is a general term for a small fly. So, what you're calling a gnat in Augusta is going to be a different insect than what they call a gnat in Pennsylvania. Gnat is a general term, typically for insects that swarm about our faces. Black flies and other gnats are attracted to the carbon dioxide in our breath.' Gray added, 'It tells them there's an animal there. Then they're going to get closer and try to pick up the final cues as to whether you're the kind of animal that they like to feed on.' 'As far as the eye gnats they're attracted to the moist membranes,' he said. 'So your eyes are where they're drawn to. For other animals, they'll get around the genitals and other places. When we say Diptera or fly that means insects that have two wings. A lot of our common insects that we deal with are a type of fly.' Different types of flies according to Gray: House flies Black flies Blow flies Mosquitoes 'So right now is peak season,' said Gray. 'Now, if it stops raining and everything starts drying up, if we go into drought conditions, the insects suffer. It's very common for the insect populations to kind of go down in the heat of the summer. If you think it's hot outside for us, well, it's hot outside for them too. Insects are very susceptible to drying out.' 'It tends to be drier from August to September,' said Gray. 'If we have a hurricane that could mean a lot of flooding. Then things start getting wet again.' 'For mosquitoes, you want to be very diligent about eliminating standing water around your homes and in your neighborhood and communities,' he said. ' Richmond County has a good mosquito control program down there in Augusta. If people are having problems with mosquitoes, they should reach out to the Richmond County Public Health to let them know what's going on.' Tips for homeowners according to the Centers for Disease Control and Prevention: Empty or throw out any items that hold water like tires, buckets, planters, toys, pools, birdbaths, flower pot saucers, or trash containers. Ensure screens are secure, free of tears, and properly installed to keep insects out while allowing fresh air in. When sleeping outdoors or in areas with poor screening, use a mosquito bed net. Wear loose-fitting, long-sleeved shirts and pants. 'I'm a homeowner,' said Gray. 'It's easy to have a bucket for picking up sticks in the yard, or the old boat that you use once in a while. So you really need to be diligent about eliminating standing water. Most of the biting flies are attracted to darker colors. So light colored, loose fitting clothing will help. If you're planning on going to a ball game or going to watch fireworks on the Fourth of July you might want to apply an EPA approved repellent to your exposed skin.' Gray said there's a lot of misinformation surrounding natural ways to get rid of pests. "The plants that have oils that can repel insects have to be crushed and processed," said Gray. "So the Citronella plant is not good. There have been studies conducted that show mosquitoes will actually land on it. Yes, citronella oil can repel mosquitoes to some degree. Oil of lemon eucalyptus is one thing that works. T's naturally derived and very effective." This reporting content is supported by a partnership with several funders and Journalism Funding Partners. Erica Van Buren is the climate change reporter for The Augusta Chronicle, part of the USA TODAY Network. Connect with her at EVanBuren@ or on X: @EricaVanBuren32. This article originally appeared on Augusta Chronicle: Impacts of extreme heat may mean more insect, pests activity
Yahoo
18 minutes ago
- Yahoo
Cosmic wonders from Chile, record heat wave and July Fourth food: The week in review
A 'cosmic treasure chest' has been opened with the debut of the Vera C. Rubin Observatory in northern Chile as astronomers released startling first images, including one of a southern region of the Virgo Cluster capturing a stunning 10 million galaxies. That was just 0.05% of the 20 billion galaxies the telescope is expected to capture with its car-sized digital camera in the coming decade. Its principal mission: the Legacy Survey of Space and Time, an ultrawide, ultra-high-definition time-lapse record of the universe, according to the facility's website − 'the largest astronomical movie of all time.' 13.5 billion years back in time: James Webb space telescope creates a vast cosmic map A dangerous heat wave smothered a large chunk of the central and eastern United States for days before easing, sending temperature records into oblivion as a huge atmospheric 'heat dome' trapped the scorching air over more than 150 million people. Baltimore's Inner Harbor soared to 104 degrees, just short of the 106 degrees in Death Valley, California. The town of North Hartland, Vermont, hit 101 degrees − hotter than Yuma, Arizona. In Paterson, New Jersey, graduation ceremonies were rescheduled for five high schools. And in the nation's capital, the Washington Monument was closed for most of the week as temperatures topped 100. Classic Fourth of July barbecues will cost a little more this year: $130 for food and drinks for a gathering of 10 people, a 2.2% increase from last year. That's according to a Wells Fargo Agri-Food Institute analysis of data from NielsenIQ, which tracks food scanned at U.S. retailers. The menu used in the analysis: barbecued chicken breasts, beef sliders, hot dogs, fruit, vegetable platter, potato salad, cornbread, cake, apple pie, ice cream, beer, wine and sodas. But lots of people will pay nothing, according to another survey by Coupon Follow − the 1 out of 3 people who don't plan to celebrate Independence Day at Morissette's early days in the music industry were no strawberry festival. When faced with the 'lovely patriarchy' of the '90s, she told The Guardian in an interview, 'there was no one to hide behind,' adding that if men in the industry could not sleep with her, 'they didn't know what to do with me.' She was more of an introvert and had trouble breaking through, she said: "So, tequila – anything that allowed me to be the life of the party. ... Anything that would help me pretend I'm not me." But now, said the singer, 51, who has been open about her addiction struggles, 'there's zero desire to present as something I'm not." Her life in pictures: Alanis Morissette through the years Oklahoma City closed out its season with a rumble heard across the NBA. The Thunder dominated the Indiana Pacers 103-91 in Game 7 of the NBA Finals, pulling ahead in the third and fourth quarters after Indiana lost star guard Tyrese Haliburton to a torn Achilles tendon late in the first quarter. The championship is Oklahoma City's first since relocating from Seattle in 2008; for the Pacers, close wasn't good enough for their second straight season with a strong playoff run before falling to the eventual NBA champs. Indiana has never won an NBA title. − Compiled and written by Robert Abitbol, USA TODAY copy chief This article originally appeared on USA TODAY: Heat wave bakes US, Chile telescope reaches for stars: Week in review
Fox News
25 minutes ago
- Fox News
Body fat predicts major health risk that BMI misses, researchers say
Body mass index (BMI) may not be the most accurate predictor of death risk. A new study from the University of Florida found that BMI — a measurement that is commonly used to determine whether a person's weight is in a healthy range for their height — is "deeply flawed" in terms of predicting mortality. Instead, one's level of body fat is "far more accurate," concluded the study, which was published this week in the Annals of Family Medicine. To measure participants' body fat, the researchers used a method called bioelectrical impedance analysis (BIA), which uses a device to measure the resistance of body tissue to a small electrical current. Over a 15-year period, those who had high body fat were found to be 78% more likely to die than those who had healthy body fat levels, researchers found. They were also more than three times as likely to die of heart disease, the study noted. BMI — which is calculated by dividing weight by height, squared — was described as "entirely unreliable" in predicting the risk of death over a 15-year period from any cause. The study included 4,252 people in the U.S. and pulled data from the National Health and Nutrition Examination Survey. BMI should not be relied upon as a "vital sign" of health, according to senior author Frank Orlando, M.D., medical director of UF Health Family Medicine in Springhill. "I'm a family physician, and on a regular basis, we're faced with patients who have diabetes, heart disease, obesity and other conditions that are related to obesity," Orlando said in a press release for the study. "One of the routine measures we take alongside traditional vital signs is BMI. We use BMI to screen for a person having an issue with their body composition, but it's not as accurate for everyone as vital signs are," he added. BMI has been the international standard for measuring obesity since the 1980s, according to many sources, though some experts have questioned its validity. "I think the study shows it's time to go to an alternative that is now proven to be far better at the job." An individual is considered obese if their BMI is 30 or above, overweight if it is between 25 and 29.9, of "normal" weight in the range of 18.5 to 24.9, or underweight if lower than 18.5. While BMI is easy to calculate, one of its main limitations is that it cannot distinguish between muscle and fat mass, the researchers noted. "For example, people who are bodybuilders can really elevate their body mass index," Orlando said. "But they're healthy even with a BMI indicating that they're obese." "BMI is just so ingrained in how we think about body fat," Mainous added. "I think the study shows it's time to go to an alternative that is now proven to be far better at the job." Other methods, such as a DEXA (dual-energy X-ray absorptiometry) scan, may be even more accurate than BIA, but are much more expensive and not as accessible, the researchers noted. "If you talk to obesity researchers, they're going to say you have to use the DEXA scan because it's the most accurate," Mainous said in the release. "And that's probably true. But it's never going to be viable in a doctor's office or family practice." Dr. Stephen Vogel — a family medicine physician with PlushCare, a virtual health platform with primary care, therapy and weight management options — echoed the limitations of BMI. "It has been an easy measurement tool that helps us understand at-risk groups across various populations and demographics, but it doesn't provide accurate data from patient to patient," the North Carolina-based doctor, who was not involved in the study, told Fox News Digital. "These findings don't challenge the assumptions about BMI — they strengthen the message that new standards, delivered in a consistent and low-cost way, would provide better nuance for the individual when it comes to their overall physical health." "The main strengths of this study are a better correlation to an individual's risk of morbidity and mortality — however, the limitations lie in the fact that we don't have enough data to determine the right cutoff for these numbers, or to identify the right tools that will be both accurate and precise across the population," Vogel said. The researchers also acknowledged that body fat percentage thresholds haven't yet been as standardized as BMI and waist circumference. Also, the age range of the participants in the study was limited by the data source. "Future studies should extend this comparison of body fat to BMI in older adults," the researchers wrote. The study was also limited by focusing only on mortality as an outcome, they noted, without taking into account any developing diseases — such as heart failure or cancer — that could deepen the understanding of body fat as a risk factor. The goal, according to Vogel, is to have a cost-effective, consistent method that can be used across the population with reliable accuracy. "These data will drive better discussions in the doctor's office, as well as public health initiatives with the goal of improving the health of all." "Benefits would come in the form of a more detailed list of information that helps providers and patients make informed decisions about the patient's health, which is ideal," Vogel noted. "I'm hopeful there's enough buzz around these measures that steps will continue to be taken toward regular implementation." For more Health articles, visit The researchers are hopeful that once standards are validated, measuring body fat percentage with bioelectrical impedance analysis could become standard of care. They added, "These data will drive better discussions in the doctor's office, as well as public health initiatives with the goal of improving the health of all."
